Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial – PubMed
NCT05008575 ( https://clinicaltrials.gov/study/NCT05008575 ).
Related Articles
Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
This nonrandomized clinical trial examines whether matched-targeted therapy based on tumor mutation status with a PD-L1 inhibitor is associated with improved overall survival among patients…
Taletrectinib Displays Efficacy, Tolerability in ROS1+ NSCLC in Multiple Clinical Trials
Investigators hope to add a treatment option that has the potential to produce superior efficacy vs present ROS1 inhibitors for patients with ROS1+ NSCLC.
NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers
NRG1 fusion positivity has gained interest as a treatment target in lung and pancreatic cancer, leading to the FDA approval of zenocutuzumab in December 2024.
Job Opportunity at University of Leeds: Research Fellow
Are you an ambitious researcher looking for your next challenge? Do you have a background in economics, econometrics, statistics, epidemiology or health data science? Are…
The Lancet Oncology
Access articles from The Lancet Oncology, covering topics that advance clinical practice, challenge the status quo, advocate change in health policy, and tackle issues related…
Outcomes of teclistamab in RRMM with prior exposure to BCMA-directed therapy
Jack Khouri, MD, Cleveland Clinic, Cleveland, OH, comments on a study investigating the outcomes of teclistamab treatment in patients with relapsed/refractory multiple myeloma (RRMM) who…
Haplotype analysis detects MLH1 founder variant in Indian Lynch syndrome patient cohort – PubMed
Lynch syndrome (LS) is an autosomal dominant hereditary cancer predisposition syndrome whereby the lifetime risk of developing gastrointestinal and genitourinary cancers rises by to over…
Sarcoma Updates from ESMO 2024: Insights from Dr. Herbert Loong
Herbert Loong, Clinical Associate Professor in the Department of Clinical Oncology at the Chinese University of Hong Kong, discusses key sarcoma updates from…
Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS
Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care.